In conclusion, our research revealed that PKC‐δ mediates rhabdomyolysis‐induced AKI via the activation of the P38MAPK and ERK1/2 pathways (Figure 7), thus providing evidence that PKC‐δ is a potent therapeutic target for rhabdomyolysis‐induced AKI. The gene discussed is MAPK3; the disease is acute kidney injury.